Valnoctamide as a valproate substitute with low teratogenic potential in mania: A double-blind, controlled, add-on clinical trial

Bipolar Disorders

Volumn 12, Issue 4, 2010, Pages 376-382

  Bersudsky, Y ^a   Applebaum, J ^a   Gaiduk, Y ^a   Sharony, L ^a   Mishory, A ^a   Podberezsky, A ^a   Agam, G ^a   Belmaker, R H ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Mania; Valnoctamide

Indexed keywords

BENZODIAZEPINE DERIVATIVE; DIAZEPAM; PLACEBO; RISPERIDONE; TRIHEXYPHENIDYL; VALNOCTAMIDE; VALPROIC ACID;

ADULT; AGED; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; MANIA; PRIORITY JOURNAL; SLEEP DISORDER; TERATOGENICITY; YOUNG MANIA RATING SCALE;

ADULT; AMIDES; ANIMALS; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MICE; MIDDLE AGED; PLACEBOS; PREGNANCY; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; TERATOGENS; TREATMENT OUTCOME; VALPROIC ACID;

EID: 77954852980     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2010.00828.x     Document Type: Article

References (42)

1. Bialer M, Haj-Yehia A, Badir K, Hadad S. Can we develop improved derivatives of valproic acid? Pharm World Sci 1994, 16:2-6.
2. Nau H, Headrick X. Valproic acid teratogenesis. ISI Atlas Sci Pharmacol 1987, 1:52-56.
3. Nau H, Hauck RS, Ehlers K. Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. Pharmacol Toxicol 1991, 69:310-321.
4. Cohen LS. Treatment of bipolar disorder during pregnancy. J Clin Psychiatry 2007, 68(Suppl. 9):4-9.
5. Nguyen HT, Sharma V, McIntyre RS. Teratogenesis associated with antibipolar agents. Adv Ther 2009, 26:281-294.
6. Newport DJ, Stowe ZN, Viguera AC. Lamotrigine in bipolar disorder: efficacy during pregnancy. Bipolar Disord 2008, 10:432-436.
7. Cunnington M, Tennis P. Lamotrigine and the risk of malformations in pregnancy. Neurology 2005, 64:955-960.
8. Bowden CL, Calabrese JR, Sachs G. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003, 60:392-400.
9. Bialer M. Pharmacokinetic considerations in the design of better and safer new antiepileptic drugs. J Control Release 1999, 62:187-192.
10. Lemoine P, Fondarai J, Faivre T. Valpromide increases amplitude of heart rate circadian rhythm in remitted bipolar and unipolar disorders. A placebo-controlled study. Eur Psychiatry 2000, 15:424-432.
11. Bialer M. Clinical pharmacology of valpromide. Clin Pharmacokinet 1991, 20:114-122.
12. Bialer M, Haj-Yehia A, Barzaghi N, Pisani F, Perucca E. Pharmacokinetics of a valpromide isomer, valnoctamide, in healthy subjects. Eur J Clin Pharmacol 1990, 38:289-291.
13. Haj-Yehia A, Bialer M. Pharmacokinetics of valpromide isomer valnoctamide in dogs. J Pharm Sci 1988, 77:831-834.
14. Pisani F, Haj-Yehia A, Fazio A. Carbamazepine-valnoctamide interaction in epileptic patients: in vitro/in vivo correlation. Epilepsia 1993, 34:954-959.
15. Loscher W, Nau H. Pharmacological evaluation of various metabolites and analogues of valproic acid. Anticonvulsant and toxic potencies in mice. Neuropharmacology 1985, 24:427-435.
16. Radatz M, Ehlers K, Yagen B, Bialer M, Nau H. Valnoctamide, valpromide and valnoctic acid are much less teratogenic in mice than valproic acid. Epilepsy Res 1998, 30:41-48.
17. α-ethyl-β-methylvaleramide for mental hyperirritability 1962, Fort Washington, PA, McNeil Laboratories Inc.
18. Bazinet RP. Is the brain arachidonic acid cascade a common target of drugs used to manage bipolar disorder? Biochem Soc Trans 2009, 37:1104-1109.
19. Rowe MK, Wiest C, Chuang DM. GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder. Neurosci Biobehav Rev 2007, 31:920-931.
20. Zhou R, Gray NA, Yuan P. The anti-apoptotic, glucocorticoid receptor cochaperone protein BAG-1 is a long-term target for the actions of mood stabilizers. J Neurosci 2005, 25:4493-4502.
21. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001, 276:36734-36741.
22. Shaltiel G, Shamir A, Shapiro J. Valproate decreases inositol biosynthesis. Biol Psychiatry 2004, 56:868-874.
23. Shaltiel G, Mark S, Kofman O, Belmaker RH, Agam G. Effect of valproate derivatives on human brain myo-inositol-1-phosphate (MIP) synthase activity and amphetamine-induced rearing. Pharmacol Rep 2007, 59:402-407.
24. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978, 133:429-435.
25. Biederman J, Lerner Y, Belmaker RH. Combination of lithium carbonate and haloperidol in schizo-affective disorder: a controlled study. Arch Gen Psychiatry 1979, 36:327-333.
26. Klein E, Bental E, Lerer B, Belmaker RH. Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses. A controlled study. Arch Gen Psychiatry 1984, 41:165-170.
27. Mishory A, Yaroslavsky Y, Bersudsky Y, Belmaker RH. Phenytoin as an antimanic anticonvulsant: a controlled study. Am J Psychiatry 2000, 157:463-465.
28. Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran A. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br J Psychiatry 2003, 182:141-147.
29. Harl FM. Clinical Study of Valnoctamide on 70 Neuropsychiatric Clinic Patients Undergoing Ambulatory Treatment (in French). Presse Med 1964, 72:753-754.
30. Overall J, Gorham D. The brief psychiatric rating scale. Psychol Rep 1962, 10:799-812.
31. Guy W. An ECDEU Assessment Manual for Psychopharmacology-Revised 1976, 218-222. Rockville, MD, U.S. Department of Health, Education and Welfare, Public Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs
32. Bialer M, Hoch B. Rapid gas chromatographic assay for monitoring valnoctamide in plasma. J Chromatogr 1985, 337:408-411.
33. Belmaker RH. Bipolar disorder. N Engl J Med 2004, 351:476-486.
34. Barel S, Yagen B, Schurig V. Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy. Clin Pharmacol Ther 1997, 61:442-449.
35. Isoherranen N, White HS, Klein BD. Pharmacokinetic-pharmacodynamic relationships of (2S,3S)-valnoctamide and its stereoisomer (2R,3S)-valnoctamide in rodent models of epilepsy. Pharm Res 2003, 20:1293-1301.
36. Bialer M, Yagen B. Valproic acid: second generation. Neurotherapeutics 2007, 4:130-137.
37. Allen MH, Hirschfeld RM, Wozniak PJ, Baker JD, Bowden CL. Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. Am J Psychiatry 2006, 163:272-275.
38. Ravindran A, Silverstone P, Lacroix D, van Schaick E, Vermeulen A, Alexander J. Risperidone does not affect steady-state pharmacokinetics of divalproex sodium in patients with bipolar disorder. Clin Pharmacokinet 2004, 43:733-740.
39. Meador KJ, Baker GA, Browning N. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 2009, 360:1597-1605.
40. Viguera AC, Whitfield T, Baldessarini RJ. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry 2007, 164:1817-1824.
41. Hirschfeld RM, Fochtmann LJ, McIntyre JS. Antidepressants for bipolar depression. Am J Psychiatry 2005, 162:1546-1547. author reply 1547-1548
42. Osher Y, Bersudsky Y, Belmaker RH. The new lithium clinic. Neuropsychobiology 2010, 62:17-26.